Xeris Biopharma XERS Stock
Xeris Biopharma Price Chart
Xeris Biopharma XERS Financial and Trading Overview
| Xeris Biopharma stock price | 7.2 USD |
| Previous Close | 6.95 USD |
| Open | 6.98 USD |
| Bid | 5.01 USD x 200 |
| Ask | 8.87 USD x 200 |
| Day's Range | 6.87 - 7.11 USD |
| 52 Week Range | 4.4 - 10.08 USD |
| Volume | 1.54M USD |
| Avg. Volume | 1.67M USD |
| Market Cap | 1.19B USD |
| Beta (5Y Monthly) | 0.898 |
| PE Ratio (TTM) | 98.57143 |
| EPS (TTM) | 0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.29 USD |
XERS Valuation Measures
| Enterprise Value | 1.34B USD |
| Trailing P/E | 98.57143 |
| Forward P/E | 17.468353 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.783449 |
| Price/Book (mrq) | 84.14634 |
| Enterprise Value/Revenue | 4.25 |
| Enterprise Value/EBITDA | 27.829 |
Trading Information
Xeris Biopharma Stock Price History
| Beta (5Y Monthly) | 0.898 |
| 52-Week Change | 49.78% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 10.08 USD |
| 52 Week Low | 4.4 USD |
| 50-Day Moving Average | 6.28 USD |
| 200-Day Moving Average | 7.04 USD |
XERS Share Statistics
| Avg. Volume (3 month) | 1.67M USD |
| Avg. Daily Volume (10-Days) | 1.81M USD |
| Shares Outstanding | 172.64M |
| Float | 163.74M |
| Short Ratio | 7.27 |
| % Held by Insiders | 3.38% |
| % Held by Institutions | 62.37% |
| Shares Short | 12.51M |
| Short % of Float | 7.50% |
| Short % of Shares Outstanding | 7.24% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 3.81% |
| Operating Margin (ttm) | 9.52% |
| Gross Margin | 85.89% |
| EBITDA Margin | 15.27% |
Management Effectiveness
| Return on Assets (ttm) | 6.34% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 314.85M USD |
| Revenue Per Share (ttm) | 1.91 USD |
| Quarterly Revenue Growth (yoy) | 38.29% |
| Gross Profit (ttm) | 270.44M USD |
| EBITDA | 48.08M USD |
| Net Income Avi to Common (ttm) | 12.01M USD |
| Diluted EPS (ttm) | 0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 111.75M USD |
| Total Cash Per Share (mrq) | 0.65 USD |
| Total Debt (mrq) | 258.55M USD |
| Total Debt/Equity (mrq) | 1987.19 USD |
| Current Ratio (mrq) | 2.122 |
| Book Value Per Share (mrq) | 0.082 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 48.53M USD |
| Levered Free Cash Flow (ttm) | 42.21M USD |
Profile of Xeris Biopharma
| Country | United States |
| State | IL |
| City | Chicago |
| Address | 1375 West Fulton Street |
| ZIP | 60607 |
| Phone | 844 445 5704 |
| Website | https://www.xerispharma.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 435 |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Q&A For Xeris Biopharma Stock
What is a current XERS stock price?
Xeris Biopharma XERS stock price today per share is 7.2 USD.
How to purchase Xeris Biopharma stock?
You can buy XERS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xeris Biopharma?
The stock symbol or ticker of Xeris Biopharma is XERS.
Which industry does the Xeris Biopharma company belong to?
The Xeris Biopharma industry is Drug Manufacturers - Specialty & Generic.
How many shares does Xeris Biopharma have in circulation?
The max supply of Xeris Biopharma shares is 172.64M.
What is Xeris Biopharma Price to Earnings Ratio (PE Ratio)?
Xeris Biopharma PE Ratio is 102.85714000 now.
What was Xeris Biopharma earnings per share over the trailing 12 months (TTM)?
Xeris Biopharma EPS is 0.07 USD over the trailing 12 months.
Which sector does the Xeris Biopharma company belong to?
The Xeris Biopharma sector is Healthcare.
Xeris Biopharma XERS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}